WO2009012039A3 - Crystalline polymorphs - Google Patents
Crystalline polymorphs Download PDFInfo
- Publication number
- WO2009012039A3 WO2009012039A3 PCT/US2008/068558 US2008068558W WO2009012039A3 WO 2009012039 A3 WO2009012039 A3 WO 2009012039A3 US 2008068558 W US2008068558 W US 2008068558W WO 2009012039 A3 WO2009012039 A3 WO 2009012039A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- crystalline polymorphs
- present
- compositions
- provides
- ethoxycarbonylprop
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides for crystalline forms of 2-amino-5-(2,2- dimethylpropionyl)-4-{[5-(N,N'-(2-ethoxycarbonylprop-2-yl)phosphonamido] furan-2-yl}thiazole and compositions thereof including pharmaceutical compositions. The present invention further provides for methods of using and processes for making the same.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94968107P | 2007-07-13 | 2007-07-13 | |
| US60/949,681 | 2007-07-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2009012039A2 WO2009012039A2 (en) | 2009-01-22 |
| WO2009012039A3 true WO2009012039A3 (en) | 2009-03-19 |
Family
ID=40260294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2008/068558 Ceased WO2009012039A2 (en) | 2007-07-13 | 2008-06-27 | Crystalline polymorphs |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2009012039A2 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| MX2018003453A (en) * | 2015-09-22 | 2019-07-04 | Viking Therapeutics Inc | Conjoint therapies with inhibitors of glucose production. |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6756360B1 (en) * | 1998-12-24 | 2004-06-29 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes |
| WO2006023515A2 (en) * | 2004-08-18 | 2006-03-02 | Metabasis Therapeutics, Inc. | Novel thiazole inhibitors of fructose 1,6-bisphosphatase |
-
2008
- 2008-06-27 WO PCT/US2008/068558 patent/WO2009012039A2/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6756360B1 (en) * | 1998-12-24 | 2004-06-29 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes |
| WO2006023515A2 (en) * | 2004-08-18 | 2006-03-02 | Metabasis Therapeutics, Inc. | Novel thiazole inhibitors of fructose 1,6-bisphosphatase |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009012039A2 (en) | 2009-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009012039A3 (en) | Crystalline polymorphs | |
| WO2008013838A3 (en) | Pyridizinone derivatives | |
| WO2009065897A3 (en) | Inhibitors of malt1 proteolytic activity and uses thereof | |
| WO2007148185A3 (en) | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors | |
| WO2007140385A3 (en) | Thiazole compounds as cannabinoid receptor ligands and uses thereof | |
| WO2008070507A3 (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
| WO2008051942A3 (en) | Farnesoid x receptor agonists | |
| EA200900282A1 (en) | APPLICATION OF POLYOLS FOR OBTAINING SUSTAINABLE POLYMORPHIC FORMS OF RIFAXIMINE | |
| WO2009016462A3 (en) | Substituted bicyclolactam compounds | |
| WO2007089768A3 (en) | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them | |
| WO2006131491A8 (en) | Polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-iminomethyl)phenylamino]methyl}-1-methyl-1h-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate | |
| WO2007076260A3 (en) | Farnesoid x receptor agonists | |
| WO2009079008A8 (en) | Benzopyrans and analogs as rho kinase inhibitors | |
| TW200745149A (en) | Crystalline form of 1'-(1-methylethyl)-4'-[(2-fluoro-4-methoxyphenyl)methyl]-5'-methyl-1H-pyrazol-3'-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments | |
| WO2007137071A3 (en) | Compositions of r(+) and s(-) pramipexole and methods of using the same | |
| IL195514A (en) | Substituted pyridyl compounds, pharmaceutical compositions comprising them, uses thereof as modulators of the histamine h3 receptor and method for their preparation | |
| WO2007020213A3 (en) | Thiazolyl piperidine derivatives useful as h3 receptor modulators | |
| WO2008135819A8 (en) | Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2- diphenylhexanamide | |
| WO2007053765A3 (en) | Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase | |
| WO2008052379A3 (en) | Organic compounds | |
| WO2008088779A3 (en) | Solid state forms of 5-azacytidine and processes for preparation thereof | |
| WO2009040314A3 (en) | Novel heteroaryl-substituted acetone derivatives, suitable for inhibiting phospholipase a2 | |
| WO2007098273A3 (en) | Novel crystalline forms of armodafinil and preparation thereof | |
| WO2007131907A3 (en) | 1h-indol-5-yl-piperazin-1-yl-methanone derivatives | |
| WO2008019030A8 (en) | Modified azole compounds as antiinfective agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08781092 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08781092 Country of ref document: EP Kind code of ref document: A2 |